Evotec SE : Return to indices in the next quarter extremely likely- attractive buying opportunity
>Tough decision by Deutsche Börse - The German stock exchange excludes Evotec from the MDax and TecDax. Since the company did not submit its 2022 Annual Report on time, the company no longer meets the requirements for index membership, the stock exchange operator said. Evotec was the victim of a cyberattack at the beginning of April and postponed the release of its annual report to 11 May (the original deadline was 30 April). From our point of view, a tough decision b...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.